Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!

Bayer Geçmiş Kazanç Performansı

Geçmiş kriter kontrolleri 0/6

Bayer yıllık ortalama 21.1% oranında kazançlarını artırırken, Pharmaceuticals sektöründe kazançlar growing at 10.8% annual. Gelirler yılda ortalama 3.3% oranında büyüyor .

Anahtar bilgiler

21.1%

Kazanç büyüme oranı

21.1%

EPS büyüme oranı

Pharmaceuticals Sektör Büyümesi	7.3%
Gelir büyüme oranı	3.3%
Özkaynak getirisi	-3.5%
Net Marj	-2.7%
Sonraki Kazanç Güncellemesi	12 Nov 2024

Yakın geçmiş performans güncellemeleri

Recent updates

These 4 Measures Indicate That Bayer (ETR:BAYN) Is Using Debt Extensively

Sep 13

Bayer Aktiengesellschaft Just Missed Earnings; Here's What Analysts Are Forecasting Now

Aug 09

These 4 Measures Indicate That Bayer (ETR:BAYN) Is Using Debt Extensively

Jun 11

The Market Doesn't Like What It Sees From Bayer Aktiengesellschaft's (ETR:BAYN) Revenues Yet

May 07

Bayer Aktiengesellschaft (ETR:BAYN) Shares Could Be 45% Below Their Intrinsic Value Estimate

Aug 05

Is Bayer (ETR:BAYN) A Risky Investment?

Jun 28

Gelir ve Gider Dağılımı

Bayer nasıl para kazanır ve harcar. LTM bazında en son bildirilen kazançlara dayanmaktadır.

Kazanç ve Gelir Geçmişi

XTRA:BAYN Gelir, gider ve kazançlar (EUR Millions )
Tarih	Gelir	Kazançlar	G+A Giderleri	Ar-Ge Giderleri
30 Jun 24	47,113	-1,266	14,696	5,742
31 Mar 24	47,013	-3,119	14,490	5,690
31 Dec 23	47,637	-2,941	14,714	5,835
30 Sep 23	47,775	-3,667	14,881	5,511
30 Jun 23	48,714	1,448	15,565	6,175
31 Mar 23	50,489	3,037	16,143	6,285
31 Dec 22	50,739	4,150	16,036	6,168
30 Sep 22	49,857	4,700	15,993	5,884
30 Jun 22	48,357	4,239	15,413	5,681
31 Mar 22	46,392	2,202	14,936	5,582
31 Dec 21	44,081	1,000	14,531	5,326
30 Sep 21	42,958	222	12,479	3,449
30 Jun 21	41,683	-7,565	13,772	5,010
31 Mar 21	40,883	-14,849	13,524	4,780
31 Dec 20	41,400	-15,569	13,886	4,884
30 Sep 20	42,155	-15,995	15,174	7,215
30 Jun 20	43,479	-7,303	13,820	5,100
31 Mar 20	44,138	2,631	14,594	5,267
31 Dec 19	43,545	2,391	14,801	5,282
30 Sep 19	43,150	-1,530	15,360	5,196
30 Jun 19	42,581	287	15,241	5,082
31 Mar 19	39,856	557	14,366	4,978
31 Dec 18	36,742	1,374	13,238	4,701
30 Sep 18	34,983	6,027	13,276	4,525
30 Jun 18	33,747	3,237	12,480	4,434
31 Mar 18	34,473	3,486	12,579	4,254
31 Dec 17	35,015	3,249	12,689	4,272
30 Sep 17	35,242	3,087	12,878	4,381
30 Jun 17	35,475	3,924	12,949	4,347
31 Mar 17	32,769	3,991	12,448	4,305
31 Dec 16	34,943	3,743	12,686	4,321
30 Sep 16	37,405	3,837	12,959	4,299
30 Jun 16	40,151	3,971	13,327	4,291
31 Mar 16	46,146	4,210	14,110	4,339
31 Dec 15	46,085	4,025	14,250	4,207
30 Sep 15	45,592	3,616	14,145	4,020
30 Jun 15	44,555	3,429	13,796	3,852
31 Mar 15	42,780	3,206	13,144	3,665
31 Dec 14	41,339	3,326	12,576	3,535
30 Sep 14	40,435	3,569	11,878	3,642
30 Jun 14	40,111	3,501	11,898	3,558
31 Mar 14	40,243	3,425	12,131	3,495
31 Dec 13	40,157	3,189	12,195	3,407

Kaliteli Kazançlar: BAYN şu anda kârlı değil.

Büyüyen Kar Marjı: BAYN şu anda kârlı değil.

Serbest Nakit Akışı ve Kazanç Analizi

Geçmiş Kazanç Büyüme Analizi

Kazanç Eğilimi: BAYN kârlı değildir, ancak son 5 yılda zararlarını yılda 21.1% oranında azaltmıştır.

Büyüme Hızlandırma: BAYN 'un son bir yıldaki kazanç büyümesinin 5 yıllık ortalamasıyla karşılaştırılması mümkün değil çünkü şu anda kârlı değil

Kazançlar vs. Sektör: BAYN kârlı olmadığından, geçmiş yıl kazanç büyümesinin Pharmaceuticals sektörüyle ( 1.5% ) karşılaştırılması zorlaşıyor.

Özkaynak Getirisi

Yüksek ROE: BAYN hissesi şu anda kârlı olmadığından negatif Özsermaye Getirisi'ne ( -3.51% ) sahiptir.

Bayer Geçmiş Kazanç Performansı

Geçmiş kriter kontrolleri 0/6

Anahtar bilgiler

Yakın geçmiş performans güncellemeleri

Second quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

First quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Full year 2023 earnings: Revenues and EPS in line with analyst expectations

Bayer Aktiengesellschaft to Report Q1, 2024 Results on May 14, 2024

Bayer Aktiengesellschaft to Report Q4, 2023 Results on Mar 05, 2024

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

Recent updates

Bayer Submits Application for Third Indication of Darolutamide in the EU

U.S. Food and Drug Administration Accepts New Drug Application for Bayer's Elinzanetant

Bayer Ag and BlueRock Therapeutics LP Announces Positive 24-Month Data from exPDite

Bayer Submits Application to U.S. FDA for Third Indication of darolutamide

These 4 Measures Indicate That Bayer (ETR:BAYN) Is Using Debt Extensively

Bayer to Unveil New Data from its Phase III OASIS 3 Long-Term Study of Elinzanetant in the Treatment of Vasomotor Symptoms Associated with Menopause

Bayer Announces Late-Breaking KERENDIA® (finerenone) Investigational Data Presented

Bayer to Present Phase III Kerendia (Finerenone) Data

Bayer Aktiengesellschaft Just Missed Earnings; Here's What Analysts Are Forecasting Now

Second quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Bayer Announces Primary Endpoint Achieved in Phase III FINEARTS-HF Cardiovascular Outcomes Study Investigating KERENDIA in Patients with Heart Failure with Mildly Reduced or Preserved Ejection Fraction

Bayer Submits New Drug Application to U.S. FDA for Elinzanetant for the Treatment of Moderate to Severe Vasomotor Symptoms Associated With Menopause

These 4 Measures Indicate That Bayer (ETR:BAYN) Is Using Debt Extensively

Bayer Presents Latest Data from Oncology Portfolio at 2024 ASCO Annual Meeting

Bayer Starts Phase I Study with Novel Targeted Radionuclide Therapy 225Ac-Psma-Trillium in Advanced Metastatic Prostate Cancer

First quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Bayer to Unveil Late-Breaking Data from Phase Iii Oasis 1 and 2 for Elinzanetant in the Treatment of Vasomotor Symptoms Associated with Menopause

The Market Doesn't Like What It Sees From Bayer Aktiengesellschaft's (ETR:BAYN) Revenues Yet

Upcoming dividend of €0.11 per share

Bayer AG and Asklepios BioPharmaceutical, Inc Presents Results from the 18-Month Phase Ib Clinical Trial for AB-1005

Bayer Appoints Sue Ann Pentecost as Head of U.S. Pharmaceutical Communications

Bayer Announces Positive Topline Results from Phase III Long-Term Study Oasis 3 Support Submits for Marketing Authorization for Bayer's Elinzanetant

Bayer Aktiengesellschaft, Annual General Meeting, Apr 25, 2025

Price target decreased by 7.7% to €42.48

Full year 2023 earnings: Revenues and EPS in line with analyst expectations

Dividend of €0.11 announced

Bayer Announces Start of Phase II Clinical Trial with BAY3018250

Bayer Aktiengesellschaft to Report Q1, 2024 Results on May 14, 2024

Bayer Aktiengesellschaft to Report Q4, 2023 Results on Mar 05, 2024

These 4 Measures Indicate That Bayer (ETR:BAYN) Is Using Debt In A Risky Way

Bayer Announces Key Leadership Changes for its Crop Science Division

Bayer Starts Phase II Study Nirvana to Evaluate Elinzanetant in Women with Sleep Disruptments Associated with Menopause

Are Investors Undervaluing Bayer Aktiengesellschaft (ETR:BAYN) By 42%?

Williams Hart & Boundas Wins Against Bayer

Price target decreased by 7.7% to €51.57

Price target decreased by 7.6% to €57.57

Bayer Announces OCEANIC-AF Study Starts Early Due to Lack of Efficacy

Bayer Issues Voluntary Recall Nationwide of VITRAKVI® (larotrectinib) Oral Solution 20 mg/mL Due to Presence of Microbial Contamination

Bayer Provides Update on Aliqopa (Copanlisib)

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

Consensus EPS estimates increase by 13%

Bayer Announces Pharmacodynamic Data on Kerendia

Bayer Aktiengesellschaft to Report Q3, 2023 Results on Nov 08, 2023

Bayer (ETR:BAYN) Takes On Some Risk With Its Use Of Debt

Bayer to Present Latest Real-World Evidence of Menopausal Symptoms and Their Treatment

Bayer Aktiengesellschaft (XTRA:BAYN) signed an agreement to acquire strawberry pipeline and commercial portfolio from NIAB.

Bayer AG and BlueRock Therapeutics LP Announces Details of the Positive Data from the Phase I Clinical Trial for Bemdaneprocel (BRT-DA01), A Stem Cell Derived Investigational Therapy for Treating Parkinson's Disease

Bayer AG and Bluerock Therapeutics LP Announces Results of the Positive Data from the Phase I Clinical Trial for Bemdaneprocel (Brt-Da01)

Bayer AG Announces Management Changes

Consensus EPS estimates fall by 11%

New minor risk - Profit margin trend

Second quarter 2023 earnings released: €1.92 loss per share (vs €0.30 loss in 2Q 2022)

Consensus EPS estimates fall by 12%

Bayer Aktiengesellschaft (ETR:BAYN) Shares Could Be 45% Below Their Intrinsic Value Estimate

Consensus EPS estimates fall by 24%

Bayer Aktiengesellschaft Provides Earnings Guidance for Full-Year 2023

Industrias Químicas del Valles S.A. reached an agreement to acquire Bayer's phytosanitary products factory in Valencia from Bayer Aktiengesellschaft (XTRA:BAYN).

Bayer Initiates Phase III Studies with Investigational Compound Agent Gadoquatrane

Is Bayer (ETR:BAYN) A Risky Investment?

FDA Approves Bayer's Ultravist® (iopromide) Injection for contrast-enhanced Mammography

Bayer to Investigate Finerenone in Phase Iii Study in Adults with Chronic Kidney Disease Associated with Type 1 Diabetes

Gelir ve Gider Dağılımı

Kazanç ve Gelir Geçmişi

Serbest Nakit Akışı ve Kazanç Analizi

Geçmiş Kazanç Büyüme Analizi

Özkaynak Getirisi

Varlık Getirisi

Kullanılan Sermaye Getirisi

Geçmişte güçlü performans gösteren şirketleri keşfedin